NCT02972957View on ClinicalTrials.gov

A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia

PHASE4CompletedINTERVENTIONAL

Enrollment

364

Participants

Timeline

Start Date

January 30, 2017

Primary Completion Date

December 19, 2018

Study Completion Date

May 23, 2019

Conditions

Influenza

Interventions

BIOLOGICAL

Nasovac-S

one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)

DRUG

Azithromycin

a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects

Trial Locations (1)

Unknown

Medical Research Council unit The Gambia, Banjul

All Listed Sponsors

collaborator

University of Edinburgh

OTHER

collaborator

Public Health England

OTHER_GOV

collaborator

University of Oxford

OTHER

collaborator

National Institute for Public Health and the Environment (RIVM)

OTHER_GOV

lead

London School of Hygiene and Tropical Medicine

OTHER

NCT02972957 - A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia | Biotech Hunter | Biotech Hunter